menu
    • menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Dietary Supplement","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Dietary Supplement","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Codeine","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Brazilian Clinical Research Institute","sponsor":"Brainfarma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metamizole","moa":"||Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Brazilian Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brazilian Clinical Research Institute \/ Brainfarma","highestDevelopmentStatusID":"10","companyTruncated":"Brazilian Clinical Research Institute \/ Brainfarma"}]

    Find Clinical Drug Pipeline Developments & Deals for Neo-Melubrina

    Menu

    Neo-Melubrina

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            EPSC
                            Not Confirmed

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Codeine,Metamizole

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Mo...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : Codeine,Metamizole

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Takeda Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

                            Details : The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business U...

                            Product Name : Neosaldina

                            Product Type : Dietary Supplement

                            Upfront Cash : Undisclosed

                            January 29, 2021

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Brazilian Clinical Research Institute

                            Country arrow
                            EPSC
                            Not Confirmed

                            Brazilian Clinical Research Institute

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metamizole,Codeine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Brainfarma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fixed Combination of Dipirone and Codeine Compared to the Isolated Use of Dipyrone and Codeine in Controlling ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 23, 2020

                            Lead Product(s) : Metamizole,Codeine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Brainfarma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Takeda Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda agrees to divest select OTC and Non core assets in Latin America to Hypera Pharma for $825 million USD

                            Details : The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.

                            Product Name : Neosaldina

                            Product Type : Dietary Supplement

                            Upfront Cash : Undisclosed

                            February 03, 2020

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ache Laboratorios Farmaceuticos SA

                            Brazil arrow
                            EPSC
                            Not Confirmed

                            Ache Laboratorios Farmaceuticos SA

                            Brazil arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate,Metamizole,Caffeine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 11, 2016

                            Lead Product(s) : Dihydroergotamine Mesylate,Metamizole,Caffeine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metamizole,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 09, 2014

                            Lead Product(s) : Metamizole,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metamizole,Diclofenac

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metamizol for the Treatment of Neoplastic Chronic Pain

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 08, 2014

                            Lead Product(s) : Metamizole,Diclofenac

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metamizole,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 08, 2014

                            Lead Product(s) : Metamizole,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mantecorp

                            Country arrow
                            EPSC
                            Not Confirmed

                            Mantecorp

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibuprofen,Metamizole,Paracetamol

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ibuprofen, Acetaminophen and Dipyrone to Fever Control in Children

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 24, 2011

                            Lead Product(s) : Ibuprofen,Metamizole,Paracetamol

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth